In a report released today, Ritu Baral from Cowen & Co. maintained a Buy rating on Krystal Biotech Inc (KRYS). The company’s shares opened today at $37.83, close to its 52-week high of $39.95.
According to TipRanks.com, Baral is a top 100 analyst with an average return of 25.2% and a 50.8% success rate. Baral covers the Healthcare sector, focusing on stocks such as Milestone Pharmaceuticals Inc, Madrigal Pharmaceuticals Inc, and ACADIA Pharmaceuticals Inc.
Currently, the analyst consensus on Krystal Biotech Inc is a Strong Buy with an average price target of $53.25, a 40.8% upside from current levels. In a report issued on June 14, H.C. Wainwright also reiterated a Buy rating on the stock with a $38 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $39.95 and a one-year low of $13.75. Currently, Krystal Biotech Inc has an average volume of 104K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Krystal Biotech, Inc. is a gene therapy company, which engages in developing and commercializing treatment for patients suffering from dermatological diseases. It developed a gene therapy platform, which company refer to as the Skin TARgeted Delivery platform, or STAR-D platform, that consists of a patent pending engineered viral vector based on herpes simplex virus 1, or HSV-1, and skin-optimized gene transfer technology, to develop off-the-shelf treatments for dermatological diseases for which company believe there are no known effective treatments. The company was founded by Suma M. Krishnan in December 2017 and is headquartered in Pittsburgh, PA.
